📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-07-30 16:52
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
44 announcements match the current filters (relevance ≥ 5).
55% Revenue Growth in Q1 FY27; Torrent Pharma Integrates JB Chemicals Acquisition
Torrent Pharma reported a robust 55% YoY revenue growth to ₹4,921 Cr for Q1 FY27, largely driven by the integration of JB Chemicals. Operating EBITDA surged 61% to ₹1,664 Cr with margins expanding to 33.8%, up from 32.5% YoY. However, PAT growth was restricted to 3% YoY (₹566 Cr) due to a significant spike in finance costs (₹293 Cr vs ₹45 Cr) and depreciation following the acquisition. The India business grew 60% YoY, with the company now ranking #1 in the Indian cardiac market.
Confidence: HIGH
What changedThe company has successfully integrated the JB Chemicals acquisition, resulting in a structural jump in revenue and market leadership in the Indian cardiac segment.
Why it mattersThe acquisition significantly scales Torrent's domestic presence and improves operating leverage, though it has temporarily increased the debt burden and interest outgo.
Q1 FY27 Revenue: ₹4,921 CrRevenue vs TTM Revenue: ~35.2%Operating EBITDA Margin: 33.8%PAT Growth (YoY): 3%India Revenue Growth: 60%Finance Costs: ₹293 Cr
📅 Short termThe market is likely to react positively to the strong EBITDA growth and margin expansion, though the high interest cost impact on PAT may temper the enthusiasm.
📈 Long termThe integration of JB Chemicals and leadership in chronic therapies (Cardiac/CNS) provides a strong structural growth runway, provided the company manages its debt effectively.
⚠ Risk flags
- High finance costs impacting net profitability
- Supply disruptions at third-party suppliers in Germany
- Regulatory risks with 8 USFDA-approved facilities
Key Highlights
Consolidated revenue increased 55% YoY to ₹4,921 Cr, with the base business growing 17% to ₹3,720 Cr.
Operating EBITDA grew 61% YoY to ₹1,664 Cr, achieving a high margin of 33.8%.
India revenues reached ₹2,890 Cr (up 60% YoY), outperforming the Indian Pharmaceutical Market (IPM) growth of 12%.
US revenues grew 36% YoY to ₹418 Cr, driven by new launches and market share gains.
Finance costs rose sharply to ₹293 Cr from ₹45 Cr YoY, reflecting the debt-funded acquisition of JB Chemicals.
👀 What to Watch
Investors should monitor the company's deleveraging progress as high interest costs are currently masking strong operational performance at the PAT level. Watch for the resolution of supply disruptions in Germany and the approval status of 58 products currently under ANVISA review in Brazil.
55% Revenue Growth in Q1 FY27; JB Chemicals Consolidation Drives Performance
Torrent Pharma reported a 55% YoY surge in consolidated revenue to ₹4,921 Cr for Q1 FY27, primarily driven by the integration of JB Chemicals. Operating EBITDA grew 61% to ₹1,664 Cr with margins expanding to 33.8%, reflecting strong operational leverage. However, Net Profit (PAT) grew only 3% to ₹566 Cr as the bottom line was weighed down by significantly higher finance costs (₹293 Cr vs ₹45 Cr) and depreciation following the acquisition. The India business remains the core driver, now contributing ₹2,890 Cr to the total revenue.
Confidence: HIGH
What changedThe formal consolidation of JB Chemicals into Torrent's financial results following the NCLT approval in July 2026, with the merger effective from January 21, 2026.
Why it mattersThis acquisition cements Torrent's position as the 5th largest player in the Indian Pharmaceutical Market and significantly strengthens its chronic therapy portfolio, particularly in cardiology and gastrointestinal segments.
Consolidated Revenue (Q1): ₹4,921 CrRevenue vs TTM Revenue: ~35.2%Operating EBITDA Margin: 33.8%JB Business Revenue: ₹1,201 CrFinance Costs (Standalone): ₹293 CrNet Profit (PAT): ₹566 Cr
📅 Short termThe market is likely to focus on the strong top-line and EBITDA growth, though the high interest and depreciation costs will keep PAT growth muted in the near term.
📈 Long termThe structural shift toward a high-margin, chronic-heavy portfolio in India provides a stable growth trajectory, provided the company successfully manages its high debt-to-equity ratio of 1.69.
⚠ Risk flags
- High debt levels (D/E 1.69) following the JB Chemicals acquisition
- Supply disruptions at third-party suppliers impacting German operations
- Regulatory risks associated with 58 products currently under ANVISA review in Brazil
Key Highlights
Consolidated Revenue reached ₹4,921 Cr, a 55% increase over Q1 FY26, including JB Chemicals' contribution.
Operating EBITDA margin improved to 33.8% from 32.5% YoY, showing enhanced profitability in the base business.
India business revenue grew 60% YoY to ₹2,890 Cr, with Torrent now ranked 1st in the Indian Cardiac market.
US revenues increased by 36% to ₹418 Cr, driven by new launches and market share gains.
Finance costs surged to ₹293 Cr from ₹45 Cr YoY, reflecting the debt servicing for the ₹25,689 Cr JB Chemicals acquisition.
👀 What to Watch
Investors should monitor the company's deleveraging progress and the realization of cost synergies from the JB Chemicals integration, while watching for any further supply disruptions in the German market.
4.19 Cr new shares of Torrent Pharma to trade from July 28 following JB Chemicals merger
Torrent Pharmaceuticals has received final listing and trading approval for 4,19,22,416 new equity shares issued to the shareholders of J.B. Chemicals & Pharmaceuticals Limited. These shares, issued pursuant to a Scheme of Amalgamation, will be admitted for trading on the NSE and BSE starting July 28, 2026. This marks the final procedural step in the massive Rs 25,689 Cr valuation merger, which significantly scales Torrent's presence in the cardiology and gastrointestinal segments. The new issuance represents a meaningful expansion of the equity base following the record date of July 17, 2026.
Confidence: HIGH
What changedThe merger between Torrent Pharma and JB Chemicals has reached its final technical milestone with the new shares becoming liquid and tradable on the stock exchanges.
Why it mattersThis acquisition is a structural shift for Torrent, making it a dominant player in the Indian chronic therapy market. It adds significant scale to its domestic business, which is currently targeting a 12% growth rate.
New shares issued: 4,19,22,416 unitsJB Chemicals Valuation: Rs 25,689 CrTrading effective date: 28-July-2026Face Value per share: Rs 5Approx Equity Dilution: 12.4%
📅 Short termThe stock may experience minor volatility as the 4.19 crore new shares enter the float, potentially leading to some liquidity-driven adjustments by new shareholders.
📈 Long termThe merger is expected to be a long-term growth engine, leveraging JB Chemicals' portfolio to outperform the Indian Pharmaceutical Market (IPM) and improve operating leverage.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Integration risks of a large-scale acquisition
- High debt levels of Rs 14,277 Cr
- Regulatory risks at manufacturing sites
Key Highlights
4,19,22,416 fully paid-up equity shares of Rs 5 each approved for listing and trading
Trading commencement date set for July 28, 2026, on both NSE and BSE
Merger involves J.B. Chemicals & Pharmaceuticals, valued at an equity valuation of Rs 25,689 Cr
Record date for the allotment of these shares was Friday, July 17, 2026
Post-merger promoter holding stands at 60.8% as of July 2026
👀 What to Watch
Investors should now focus on the operational integration of JB Chemicals and the realization of cost synergies to support the current 32.6% OPM. Monitor upcoming quarterly results for the first full consolidated financial performance of the merged entity.
4.19 Cr shares allotted to JB Chemicals shareholders following merger completion
Torrent Pharmaceuticals has finalized the allotment of 4,19,22,416 equity shares to the shareholders of J.B. Chemicals & Pharmaceuticals Limited (JB Chemicals). This action follows the NCLT-sanctioned Scheme of Amalgamation, effectively integrating JB Chemicals into Torrent. The allotment results in a 12.39% equity dilution, increasing the total share count from 33.84 crore to 38.04 crore shares. This merger is a major strategic move, valued at approximately ₹25,689 crore, aimed at scaling Torrent's presence in the cardiology and gastrointestinal segments.
Confidence: HIGH
What changedTorrent Pharma has officially issued new shares to JB Chemicals shareholders, completing the equity swap phase of their merger.
Why it mattersThis is a transformative acquisition for Torrent, significantly increasing its market share in the Indian Pharmaceutical Market (IPM) and strengthening its high-margin branded generic portfolio.
Shares Allotted: 4,19,22,416Equity Dilution: ~12.39%Post-Allotment Share Capital: ₹190.18 CrJB Chemicals Valuation: ₹25,689 CrSwap Ratio: 51:100
📅 Short termThe stock may experience minor volatility as the 4.19 crore new shares are credited and become available for trading by former JB Chemicals shareholders.
📈 Long termThe merger is structurally significant, positioning Torrent to outperform the IPM through enhanced scale in chronic therapies and expanded footprints in India and South Africa.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Integration risks of a large-scale acquisition
- EPS dilution due to the 12.4% increase in share capital
- High Debt-to-Equity ratio of 1.69
Key Highlights
Allotment of 4,19,22,416 fully paid-up equity shares of ₹5 each to JB Chemicals shareholders.
Share exchange ratio fixed at 51 Torrent Pharma shares for every 100 JB Chemicals shares.
Total issued and paid-up equity capital increased from ₹169.22 Cr to ₹190.18 Cr.
The merger integrates JB Chemicals, which has a total equity valuation of ₹25,689 Cr.
Record date for the share allotment was July 17, 2026.
👀 What to Watch
Investors should monitor the upcoming quarterly results to assess the successful integration of JB Chemicals' operations and the realization of cost synergies, particularly in the chronic therapy segments.
Torrent Pharma Completes JB Chemicals Merger; Authorized Capital Revised to ₹255.30 Cr
Torrent Pharmaceuticals has officially completed the amalgamation of J.B. Chemicals & Pharmaceuticals Limited (JB Chemicals), effective July 8, 2026. The merger, previously sanctioned by the NCLT Ahmedabad, results in the dissolution of JB Chemicals without winding up. The appointed date for the scheme is January 21, 2026. Consequently, Torrent's authorized share capital has been revised to ₹255.30 Cr, reflecting the integration of the two entities.
Confidence: HIGH
What changedJB Chemicals has been legally dissolved and merged into Torrent Pharma, and the Memorandum of Association (MOA) has been amended to reflect the new combined capital structure.
Why it mattersThis is a transformative acquisition that significantly scales Torrent's domestic branded business, particularly in chronic therapies, and is expected to improve operating margins through synergy and scale.
New Authorized Capital: ₹255.30 CrJB Chemicals Valuation: ₹25,689 CrValuation vs TTM Revenue: 183.7%Effective Date: 8th July, 2026Appointed Date: 21st January, 2026
📅 Short termThe completion of the merger removes legal uncertainty, which is likely to be viewed positively by the market as the company begins full operational integration.
📈 Long termThe merger structurally enhances Torrent's position as the 5th largest player in the Indian pharma market, providing long-term growth levers in branded generics and chronic segments.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Integration risk of a large-scale entity
- High Debt-to-Equity ratio (1.69)
- Regulatory risks at manufacturing sites
Key Highlights
Scheme of Amalgamation became effective on July 8, 2026, following the filing of NCLT orders with the ROC.
The Appointed Date for the merger is retrospectively set as January 21, 2026.
Authorized share capital increased to ₹255.30 Cr, consisting of 46.06 Cr equity shares of ₹5 each and 25 lakh preference shares.
The acquisition of JB Chemicals was valued at approximately ₹25,689 Cr, representing ~183% of Torrent's TTM revenue.
👀 What to Watch
Investors should monitor the upcoming quarterly results for the first consolidated financial performance and track the progress of cost synergies in the cardiology and gastrointestinal segments. The focus should also remain on the management's plan to deleverage, given the current debt of ₹14,277 Cr.
₹25,689 Cr Merger Effective: Torrent Pharma Completes J.B. Chemicals Amalgamation
Torrent Pharmaceuticals has officially completed the amalgamation of J.B. Chemicals & Pharmaceuticals Limited, effective July 8, 2026. The merger, based on an equity valuation of ₹25,689 Cr, follows the NCLT Ahmedabad Bench's approval and subsequent filing with the Registrar of Companies. The appointed date for the merger is January 21, 2026, which will lead to retroactive financial consolidation. This acquisition is a major strategic move to scale Torrent's presence in the cardiology and gastrointestinal segments in India.
Confidence: HIGH
What changedJ.B. Chemicals has officially merged into Torrent Pharmaceuticals, ceasing to exist as a separate entity and becoming a fully integrated part of Torrent's operations.
Why it mattersThis is a transformative acquisition that solidifies Torrent's position as the 5th largest player in the Indian pharmaceutical market, specifically strengthening its high-margin chronic therapy portfolio.
J.B. Chemicals Equity Valuation: ₹25,689 CrNew Authorized Capital: ₹255.30 CrAppointed Date: January 21, 2026Valuation vs Torrent Market Cap: ~15.6%TTM Revenue (Pre-merger): ₹13,980 Cr
📅 Short termThe completion of legal formalities removes uncertainty, likely providing a positive sentiment boost as the market anticipates the benefits of the combined entity.
📈 Long termStructurally positive as it provides significant scale in the domestic branded formulations market and offers synergy opportunities in manufacturing and supply chain.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Integration risks of a large-scale entity
- High Debt-to-Equity ratio (1.69) post-acquisition
- Potential for short-term EPS dilution depending on funding structure
Key Highlights
Amalgamation became effective on July 8, 2026, following ROC filing of the NCLT order.
The Appointed Date for the scheme is January 21, 2026, impacting prior period financials.
J.B. Chemicals equity valuation stands at ₹25,689 Cr, representing ~15.6% of Torrent's market cap.
Authorized share capital of Torrent Pharma increased to ₹255.30 Cr to accommodate the merger.
J.B. Chemicals stands dissolved without being wound up as of the effective date.
👀 What to Watch
Investors should monitor the next quarterly results for the first set of consolidated financials including J.B. Chemicals. Key metrics to watch include the impact on operating margins (currently 32.6%) and the management's plan to deleverage the balance sheet (D/E ratio 1.69).
51:100 Swap: Torrent Pharma Sets July 17 Record Date for JB Chemicals Merger
Torrent Pharma has fixed July 17, 2026, as the record date for its merger with J.B. Chemicals & Pharmaceuticals. Eligible shareholders of JB Chemicals will receive 51 shares of Torrent Pharma (₹5 face value) for every 100 shares of JB Chemicals (₹1 face value) held. This follows the NCLT Ahmedabad Bench's approval on July 6, 2026. The acquisition, valued at ₹25,689 Cr, is a major strategic move to scale Torrent's cardiology and gastrointestinal segments.
Confidence: HIGH
What changedThe merger between Torrent Pharma and JB Chemicals has reached the final execution stage with the announcement of the record date for share swap.
Why it mattersThis merger consolidates Torrent's position as the 5th largest player in the Indian pharmaceutical market, significantly expanding its chronic therapy footprint and manufacturing capacity.
Share Swap Ratio: 51:100Record Date: 17-Jul-2026JB Chemicals Valuation: ₹25,689 CrValuation vs Torrent M-Cap: ~15.6%Torrent Debt: ₹14,277 Cr
📅 Short termThe stock may see increased trading activity and volatility leading up to the July 17 record date as the merger swap is finalized.
📈 Long termStructurally positive as it integrates JB Chemicals' high-growth chronic business, though long-term success depends on capturing cost synergies and managing the combined debt profile.
⚠ Risk flags
- Integration of large-scale manufacturing operations
- High debt-to-equity ratio of 1.69
- Potential EPS dilution post-merger
Key Highlights
Record date for share allotment fixed for July 17, 2026
Share exchange ratio set at 51 Torrent Pharma shares for every 100 JB Chemicals shares
JB Chemicals equity valuation involved in the scheme is ₹25,689 Cr
NCLT Ahmedabad Bench sanctioned the scheme of amalgamation on July 6, 2026
Torrent Pharma face value is ₹5 per share compared to JB Chemicals' ₹1 per share
👀 What to Watch
Monitor the record date of July 17 for share entitlement and watch for the subsequent listing of new shares. Post-merger, focus on the integration of JB Chemicals' portfolio and its impact on Torrent's 32.6% operating margins and ₹14,277 Cr debt levels.
NCLT Sanctions Rs 25,689 Cr Merger of J.B. Chemicals with Torrent Pharmaceuticals
Torrent Pharmaceuticals has received the certified NCLT order sanctioning the amalgamation of J.B. Chemicals & Pharmaceuticals Limited. This transformative deal, valued at Rs 25,689 Cr, represents approximately 184% of Torrent's TTM revenue of Rs 13,980 Cr. The merger is expected to significantly bolster Torrent's position as the 5th largest player in the Indian pharmaceutical market, particularly in cardiology and gastrointestinal segments. The receipt of the certified copy is a critical final step toward the legal completion of the merger.
Confidence: HIGH
What changedThe legal hurdle for the merger is cleared with the NCLT sanctioning the scheme, allowing Torrent to proceed with the final integration of J.B. Chemicals.
Why it mattersThis is a massive consolidation in the Indian pharma space, significantly increasing Torrent's market share and therapeutic reach while offering substantial cost and revenue synergies.
J.B. Chemicals Valuation: Rs 25,689 CrDeal Value vs TTM Revenue: ~184%TTM Revenue: Rs 13,980 CrNCLT Order Date: 6th July, 2026Certified Copy Receipt: 7th July, 2026
📅 Short termPositive sentiment is expected as the legal process for a massive, growth-oriented acquisition nears completion.
📈 Long termTransformative for the company's domestic formulations business; success depends on the integration of JB Chemicals' supply chain and capturing cost synergies to improve OPM from the current 32.6%.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Integration risks of a large-scale entity
- High Debt-to-Equity ratio of 1.69
- Potential regulatory scrutiny post-merger
Key Highlights
NCLT Ahmedabad Bench sanctioned the Scheme of Amalgamation on 6th July, 2026
Certified true copy of the order received by the company on 7th July, 2026
Acquisition valuation of J.B. Chemicals is approximately Rs 25,689 Cr
Torrent's TTM revenue stands at Rs 13,980 Cr, making the deal value ~1.8x annual revenue
Merger targets scale in cardiology and gastro segments where Torrent already has a strong chronic presence
👀 What to Watch
Monitor the filing of the order with the Registrar of Companies (ROC) to mark the 'Effective Date' and track the integration of J.B. Chemicals' high-margin chronic portfolio in upcoming quarterly results.
Rs 25,689 Cr Merger: NCLT Sanctions Amalgamation of J.B. Chemicals with Torrent Pharma
The Hon’ble NCLT, Ahmedabad Bench, has officially sanctioned the Scheme of Amalgamation of J.B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals on July 6, 2026. This merger follows a massive acquisition valuation of Rs 25,689 Cr, which is approximately 184% of Torrent's TTM revenue of Rs 13,980 Cr. The consolidation is expected to significantly scale Torrent's presence in the cardiology and gastrointestinal segments. The scheme will become legally effective once the certified order is filed with the Registrar of Companies.
Confidence: HIGH
What changedThe legal approval process for the merger of J.B. Chemicals into Torrent Pharmaceuticals has been completed with the NCLT's final order.
Why it mattersThis is a transformative deal that significantly increases Torrent's scale in the Indian branded formulations market, particularly in high-margin chronic therapies. It represents a major capital allocation move involving a valuation nearly double the company's annual revenue.
J.B. Chemicals Valuation: Rs 25,689 CrValuation vs TTM Revenue: 183.7%TTM Revenue: Rs 13,980 CrNCLT Order Date: July 6, 2026Current Debt: Rs 14,277 Cr
📅 Short termThe stock is likely to react positively as the regulatory uncertainty regarding the merger approval is now resolved.
📈 Long termThe merger structurally alters Torrent's market position, potentially leading to higher market share in the Indian Pharmaceutical Market and long-term cost synergies in manufacturing and supply chain.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Integration risk of a large-scale acquisition
- High debt-to-equity ratio (1.69)
- Regulatory pricing controls in the Indian market
Key Highlights
NCLT Ahmedabad Bench sanctioned the merger order on July 6, 2026
Acquisition involves a total equity valuation of Rs 25,689 Cr for J.B. Chemicals
Torrent's chronic business is currently growing at 13%, which this merger aims to accelerate
Torrent is currently the 5th largest player in the Indian pharmaceutical market
The company reported a TTM revenue of Rs 13,980 Cr and OPM of 32.6% prior to this consolidation
👀 What to Watch
Investors should monitor the announcement of the 'Effective Date' following the RoC filing and track the integration process. Key metrics to watch in upcoming quarters include the impact on operating margins (currently 32.6%) and the management of the company's debt-to-equity ratio, which stands at 1.69.
Torrent Pharma Shareholders Approve ₹9 Final Dividend and Fundraise at 53rd AGM
Torrent Pharmaceuticals Limited held its 53rd Annual General Meeting on June 23, 2026, where shareholders approved all proposed resolutions with significant majorities. Key approvals included the adoption of FY2025-26 financial statements and a final dividend of ₹9.00 per share, bringing the total dividend for the year to ₹38.00 per share. Additionally, shareholders passed a special resolution for the potential issuance of equity shares or convertible bonds/debentures. The re-appointment of Samir Mehta as Director was also confirmed with 98.74% of the votes.
Key Highlights
Approved a final dividend of ₹9.00 per share, resulting in a total FY26 payout of ₹38.00 per share.
Shareholders greenlit an enabling resolution for fundraising through equity or convertible instruments with 99.93% approval.
Standalone and Consolidated Financial Statements for the year ended March 31, 2026, were adopted with 100% favor.
Samir Mehta was re-appointed as Director with 30.92 crore votes in favor (98.74%).
Ratification of Cost Auditors' remuneration for the financial year 2026-27 was approved.
👀 What to Watch
Investors should monitor the company's future announcements regarding the specific timing and size of any potential fundraise enabled by the approved resolution. The steady dividend payout reflects a stable financial position, but no immediate portfolio changes are required based on these routine approvals.
Torrent Pharma 53rd AGM: Total Dividend of ₹38/Share Confirmed & Fundraise Approved
Torrent Pharmaceuticals concluded its 53rd Annual General Meeting, confirming a total dividend of ₹38.00 per share for FY 2025-26, which includes a ₹29.00 interim and ₹9.00 final dividend. Shareholders approved the audited financial statements for the year ended March 31, 2026, and authorized the board to raise funds through equity shares or convertible instruments. The meeting also saw the re-appointment of Samir Mehta as Director and the ratification of cost auditor remuneration.
Key Highlights
Confirmed total dividend payout of ₹38.00 per equity share (face value ₹5.00) for FY 2025-26.
Approved the issuance of Equity Shares, including Convertible Bonds and Debentures for future capital requirements.
Adopted Standalone and Consolidated Audited Financial Statements for the fiscal year ending March 31, 2026.
Re-appointed Samir Mehta (DIN: 00061903) as Director following retirement by rotation.
Ratified the remuneration for the company's cost auditors for the 2026-27 period.
👀 What to Watch
Investors should track the record date for the ₹9.00 final dividend and monitor subsequent filings for details on the size and pricing of the approved fundraise.
Torrent Pharma Sets May 29, 2026, as Record Date for Final Dividend
Torrent Pharmaceuticals Limited has officially fixed Friday, May 29, 2026, as the record date for determining shareholder eligibility for the final dividend of the financial year 2025-26. The announcement was made on May 22, 2026, in compliance with SEBI Listing Regulations. This dividend is applicable to equity shares with a face value of ₹5 each. The actual payment remains subject to formal declaration by the company.
Key Highlights
Record date for final dividend eligibility is May 29, 2026
Dividend pertains to the financial year 2025-26
Applicable to equity shares with a face value of ₹5 each
Official notification issued to stock exchanges on May 22, 2026
👀 What to Watch
Investors seeking to receive the dividend should ensure they hold the stock before the ex-dividend date, which typically precedes the record date. No action is required for existing long-term shareholders.
Torrent Pharma FY26 Net Profit Rises 16% to ₹2,192 Cr; Proposes ₹5,000 Cr Fundraise
Torrent Pharmaceuticals reported a steady financial performance for the fiscal year ended March 31, 2026, with annual revenue growing 10.6% to ₹10,712 crore. The company's full-year net profit increased by 16.1% to ₹2,192 crore compared to ₹1,888 crore in the previous year. A final dividend of ₹9 per share has been recommended, bringing the total dividend for FY26 to ₹38 per share. Furthermore, the board has sought an enabling approval to raise up to ₹5,000 crore through QIP or other equity-linked instruments for future growth requirements.
Key Highlights
Annual revenue from operations increased to ₹10,712 crore in FY26 from ₹9,682 crore in FY25.
Net profit for the full year FY26 grew by 16.1% YoY to reach ₹2,192 crore.
Recommended a final dividend of ₹9 per share (180%), with the record date set for May 29, 2026.
Board approved a massive enabling resolution to raise up to ₹5,000 crore via QIP or convertible bonds.
Standalone Q4 FY26 revenue stood at ₹2,735 crore, representing a 12.4% growth over Q4 FY25.
👀 What to Watch
Investors should maintain a positive outlook given the consistent double-digit growth in annual profits and a healthy dividend payout. The proposed ₹5,000 crore fundraise indicates management's readiness for potential strategic acquisitions or significant expansion.
Torrent Pharma FY26 Net Profit Up 16% to ₹2,192 Cr; Proposes ₹5,000 Cr Fundraise
Torrent Pharmaceuticals reported a solid performance for the full year ended March 31, 2026, with total revenue growing 11% to ₹10,712 crore. Full-year net profit increased by 16% YoY to reach ₹2,192 crore, although Q4 standalone profit was slightly lower at ₹467 crore compared to ₹474 crore in the previous year. The company has recommended a final dividend of ₹9 per share, taking the total dividend for FY26 to ₹38 per share. Furthermore, the board has sought enabling approval to raise up to ₹5,000 crore through QIP or other modes, indicating potential expansion or balance sheet strengthening.
Key Highlights
Annual Revenue from operations grew 11% YoY to ₹10,712 crore in FY26.
Full-year Net Profit increased by 16% to ₹2,192 crore from ₹1,888 crore in FY25.
Recommended a final dividend of ₹9 per share (180%), with a record date of May 29, 2026.
Board approved enabling resolution for a fundraise up to ₹5,000 crore via QIP or convertible bonds.
Finance costs for Q4 FY26 rose significantly to ₹225 crore compared to ₹47 crore in the year-ago quarter.
👀 What to Watch
The strong annual earnings growth and healthy dividend payout reflect robust fundamentals. Investors should monitor the utilization of the proposed ₹5,000 crore fundraise, as it may signal upcoming M&A activity or strategic expansions.
Torrent Pharma Q4 Revenue Surges 42% YoY to Rs 4,197 Cr; India Sales Up 43%
Torrent Pharmaceuticals reported a robust 42% year-on-year growth in Q4 FY26 revenue, reaching Rs 4,197 crore. The domestic market (India) performed exceptionally well with a 43% increase in Q4, while the US and Brazil markets grew by 31% and 30% respectively. For the full fiscal year 2026, total revenue rose by 21% to Rs 13,980 crore. This strong performance across all key geographies indicates high operational momentum and successful market penetration.
Key Highlights
Q4 FY26 total revenue grew by 42% YoY to Rs 4,197 crore compared to Rs 2,959 crore in Q4 FY25.
India business, the largest segment, saw a massive 43% growth in Q4 FY26, reaching Rs 2,215 crore.
Full-year FY26 revenue increased by 21% to Rs 13,980 crore, driven by strong performance in India and Brazil.
US revenue showed a healthy recovery with 31% growth in Q4 FY26 and 24% growth for the full year.
The 'Others' segment witnessed the highest Q4 growth at 68%, contributing Rs 798 crore to the topline.
👀 What to Watch
Investors should view this as a strong positive signal, especially given the robust growth in the high-margin India business. Maintain a positive outlook while monitoring margin sustainability in the detailed financial reports.
Torrent Pharma FY26 Net Profit Rises 16% to ₹2,192 Cr; Proposes ₹5,000 Cr Fundraise
Torrent Pharmaceuticals reported a steady performance for FY26 with standalone revenue growing 10.6% YoY to ₹10,712 crores. Net profit for the full year increased by 16% to ₹2,192 crores, although Q4 standalone profit saw a marginal dip to ₹467 crores compared to ₹474 crores in the previous year's quarter. The board has recommended a final dividend of ₹9 per share, bringing the total dividend for the year to ₹38. Additionally, the company is seeking approval to raise up to ₹5,000 crores through QIP or other modes, indicating potential expansion or inorganic growth plans.
Key Highlights
FY26 Standalone Revenue increased by 10.6% YoY to ₹10,712 crores compared to ₹9,682 crores in FY25.
Annual Standalone Net Profit grew 16% to ₹2,192 crores from ₹1,888 crores in the previous fiscal year.
Board recommended a final dividend of ₹9 per share (180%), taking the total FY26 dividend to ₹38 per share.
Approved an enabling resolution to raise up to ₹5,000 crores via QIP or convertible debentures.
Finance costs for the full year rose to ₹341 crores from ₹213 crores in FY25, reflecting higher debt servicing or borrowing.
👀 What to Watch
Investors should focus on the management's commentary regarding the ₹5,000 crore fundraise, as it likely signals a major acquisition. The stock remains a solid pick for dividend-seeking investors given the total payout of ₹38 per share.
Torrent Pharma Declares ₹9 Final Dividend; FY26 Net Profit Rises 16% to ₹2,192 Cr
Torrent Pharmaceuticals has reported a strong financial performance for FY26, with standalone net profit increasing by 16% to ₹2,192 crore. The Board has recommended a final dividend of ₹9 per share, which, combined with the interim dividend of ₹29, brings the total payout to ₹38 for the year. Furthermore, the company is seeking enabling approval to raise up to ₹5,000 crore through QIP or other modes. Revenue from operations grew by 10.6% year-on-year to reach ₹10,712 crore.
Key Highlights
Recommended a final dividend of ₹9 per equity share (180%) with a record date of May 29, 2026.
Full-year standalone net profit grew to ₹2,192 crore in FY26 from ₹1,888 crore in FY25.
Total annual revenue from operations increased to ₹10,712 crore, up from ₹9,682 crore in the previous fiscal.
Board approved a proposal to raise up to ₹5,000 crore via QIP or Convertible Bonds/Debentures.
Total dividend for FY26 stands at ₹38 per share, including the ₹29 interim dividend already paid.
👀 What to Watch
Investors should maintain a positive outlook given the steady profit growth and high dividend yield; the proposed ₹5,000 crore fundraise suggests potential for future inorganic expansion.
Torrent Pharma Shareholders Approve Merger with J.B. Chemicals with 100% Votes in Favor
Torrent Pharmaceuticals' shareholders have overwhelmingly approved the Scheme of Amalgamation with J.B. Chemicals & Pharmaceuticals Limited. In an NCLT-convened meeting held on April 28, 2026, 100% of the valid votes cast by value were in favor of the merger. The consolidated voting results showed participation from 1,202 shareholders, representing over 31.73 crore votes. This approval marks a critical step in the regulatory process for the merger of these two pharmaceutical companies.
Key Highlights
100% of valid votes by value were cast in favor of the amalgamation with J.B. Chemicals & Pharmaceuticals.
A total of 31,73,30,454 votes were polled, representing a value of INR 1,58,66,52,270.
Promoter group cast 23,11,85,400 votes, all of which were in favor of the resolution.
Public shareholders cast 8,38,11,400 valid votes, with only 341 votes cast against the scheme.
The meeting was conducted via video conferencing as per the NCLT Ahmedabad Bench order dated March 23, 2026.
👀 What to Watch
The strong shareholder mandate clears a major hurdle for the merger; investors should now monitor the final NCLT sanction and the subsequent integration of J.B. Chemicals' portfolio.
Torrent Pharma Shareholders Approve Merger with J.B. Chemicals with 99.99% Majority
Shareholders of Torrent Pharmaceuticals have overwhelmingly approved the Scheme of Amalgamation with J.B. Chemicals & Pharmaceuticals Limited in an NCLT-convened meeting held on April 28, 2026. A total of 31.73 crore votes were polled, with 99.99% of the total value of valid votes cast in favor of the merger. Both promoter and public shareholders showed near-unanimous support for the consolidation. This approval marks a critical regulatory milestone in the merger process, moving the company closer to final integration.
Key Highlights
Shareholders approved the merger of J.B. Chemicals & Pharmaceuticals with Torrent Pharma by a requisite three-fourth majority in value.
A total of 31,73,30,454 votes were polled, representing a significant portion of the 33.84 crore total equity shares.
Consolidated results show 31,49,96,459 votes were cast in favor, representing nearly 100% of the valid value polled.
Promoter group cast 23,11,85,400 votes, all of which were 100% in favor of the amalgamation scheme.
Only 341 votes were cast against the resolution, indicating negligible opposition from the minority shareholders.
👀 What to Watch
Investors should view this near-unanimous shareholder approval as a strong mandate for the merger's synergy potential. Continue to monitor the final NCLT sanction and the subsequent integration of J.B. Chemicals' portfolio into Torrent's operations.
Torrent Pharma Shareholders Approve Merger with J.B. Chemicals & Pharmaceuticals
Shareholders of Torrent Pharmaceuticals have officially approved the Scheme of Amalgamation with J.B. Chemicals & Pharmaceuticals Limited in an NCLT-convened meeting held on April 28, 2026. The resolution was passed with the requisite majority, satisfying the requirement of a majority in number and three-fourths in value of the shareholders who cast their votes. This approval is a critical milestone in the merger process, which aims to consolidate the operations of both pharmaceutical entities. The company will now proceed with the remaining regulatory steps to finalize the transaction.
Key Highlights
Shareholders approved the merger of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited.
The resolution passed with a majority in number and 75% in value of the equity shareholders who voted.
The NCLT-convened meeting was conducted via video conferencing on April 28, 2026, concluding in 21 minutes.
Compliance with Section 230(6) of the Companies Act, 2013, has been achieved for this shareholder vote.
👀 What to Watch
Investors should view this as a positive step toward scale and synergy; monitor the final NCLT approval and the subsequent integration process for long-term value creation.
